Clinical Trials Logo

Pancreatic Tumours clinical trials

View clinical trials related to Pancreatic Tumours.

Filter by:
  • None
  • Page 1

NCT ID: NCT02651987 Completed - Clinical trials for Midgut Neuroendocrine Tumours

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

CLARINET FORTE
Start date: December 15, 2015
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.